Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study

Journal of Clinical Oncology

Volumn 31, Issue 33, 2013, Pages 4252-4259

  Thomas, Nancy E ^a   Busam, Klaus J ^b   From, Lynn ^c   Kricker, Anne ^e   Armstrong, Bruce K ^e   Anton Culver, Hoda ^g   Gruber, Stephen B ^h   Gallagher, Richard P ^d   Zanetti, Roberto ⁱ   Rosso, Stefano ⁱ   Dwyer, Terence ^j   Venn, Alison ^f   Kanetsky, Peter A ^k   Groben, Pamela A ^a   Hao, Honglin ^a   Orlow, Irene ^b   Reiner, Anne S ^b   Luo, Li ^l   Paine, Susan ^l   Ollila, David W ^a   Wilcox, Homer ^m   Begg, Colin B ^b   Berwick, Marianne ^a,c   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF TASMANIA   (Australia)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ Center for Cancer Prevention Piemonte   (Italy)

^j INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY OF NEW MEXICO   (United States)

^m NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; FEMALE; GROWTH CURVE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; THICKNESS; TUMOR ASSOCIATED LEUKOCYTE; CLINICAL TRIAL; FOLLOW UP; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HEALTH SURVEY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; SKIN TUMOR; SURVIVAL RATE; TIME; METHODOLOGY;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GENE-ENVIRONMENT INTERACTION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 84892945383     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.3002     Document Type: Article

References (34)

1. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
2. Elder DE, Guerry D 4th, VanHorn M, et al: The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 56:413-418, 1985 (Pubitemid 15031668)
3. Clark WH Jr, Elder DE, Guerry D 4th, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989 (Pubitemid 20026075)
4. Elder DE, Gimotty PA, Guerry D: Cutaneous melanoma: Estimating survival and recurrence risk based on histopathologic features. Dermatol Ther 18:369-385, 2005 (Pubitemid 43096610)
5. Clemente CG, Mihm MC Jr, Bufalino R, et al: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310, 1996 (Pubitemid 26102328)
6. Tuthill RJ, Unger JM, Liu PY, et al: Risk assessment in localized primary cutaneous melanoma: A Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 118: 504-511, 2002 (Pubitemid 44698506)
7. Rao UN, Lee SJ, Luo W, et al: Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: Pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol 133: 646-653, 2010
8. Azimi F, Scolyer RA, Rumcheva P, et al: Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30:2678-2683, 2012
9. Grotz TE, Vaince F, Hieken TJ: Tumorinfiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes. Melanoma Res 23:132-137, 2013
10. Mandalà M, Imberti GL, Piazzalunga D, et al: Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database. Eur J Cancer 45: 2537-2545, 2009
11. Taylor RC, Patel A, Panageas KS, et al: Tumorinfiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25:869-875, 2007 (Pubitemid 350002888)
12. Barnhill RL, Fine JA, Roush GC, et al: Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78: 427-432, 1996 (Pubitemid 26250527)
13. Begg CB, Hummer A, Mujumdar U, et al: Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control 15:957-965, 2004 (Pubitemid 39663872)
14. Begg CB, Hummer AJ, Mujumdar U, et al: A design for cancer case-control studies using only incident cases: Experience with the GEM study of melanoma. Int J Epidemiol 35:756-764, 2006 (Pubitemid 43985574)
15. Millikan RC, Hummer A, Begg C, et al: Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: The Genes Environment and Melanoma Study. Carcinogenesis 27:610-618, 2006 (Pubitemid 43378899)
16. Clark WH Jr, From L, Bernardino EA, et al: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705-727, 1969
17. McGovern VJ, Mihm MC Jr, Bailly C, et al: The classification of malignant melanoma and its histologic reporting. Cancer 32:1446-1457, 1973
18. Piris A, Mihm MC Jr, Duncan LM: AJCC melanoma staging update: Impact on dermatopathology practice and patient management. J Cutan Pathol 38:394-400, 2011
19. Lachiewicz AM, Berwick M, Wiggins CL, et al: Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol 144:515-521, 2008 (Pubitemid 351581109)
20. Tseng WH, Martinez SR: Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res 167:192-198, 2011
21. Green AC, Baade P, Coory M, et al: Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 30:1462-1467, 2012
22. Selvin S: A note on the power to detect interaction effects, in Kesley J, Marmot M, Stolley P, et al (eds): Statistical Analysis of Epidemiologic Data. New York, NY, Oxford University Press, 1996, pp 213-214
23. Gershenwald JE, Soong SJ, Balch CM: 2010 TNM staging system for cutaneous melanoma . . . and beyond. Ann Surg Oncol 17:1475-1477, 2010
24. Gomez CR, Nomellini V, Faunce DE, et al: Innate immunity and aging. Exp Gerontol 43:718-728, 2008
25. Oble DA, Loewe R, Yu P, et al: Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3, 2009
26. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
27. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
28. Edlundh-Rose E, Egyházi S, Omholt K, et al: NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing. Melanoma Res 16:471-478, 2006 (Pubitemid 44934704)
29. Busam KJ, Antonescu CR, Marghoob AA, et al: Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma: A study of interobserver agreement. Am J Clin Pathol 115:856-860, 2001 (Pubitemid 32476712)
30. van Houdt IS, Sluijter BJ, Moesbergen LM, et al: Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 123: 609-615, 2008 (Pubitemid 351898419)
31. Jensen TO, Schmidt H, Møller HJ, et al: Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 118:2476-2485, 2012
32. Taube JM, Anders RA, Young GD, et al: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37, 2012
33. Ji RR, Chasalow SD, Wang L, et al: An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61:1019-1031, 2012
34. Gajewski TF, Louahed J, Brichard VG: Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy. Cancer J 16:399-403, 2010